Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial (Q36630742)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 December 2012

Language	Label	Description	Also known as
English	Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial	scientific article published on 18 December 2012

Statements

scholarly article

1 reference

Europe PubMed Central

15 August 2017

Prognosis significance of HER-2/neu overexpression/amplification in Chinese patients with curatively resected gastric cancer after the ToGA clinical trial (English)

1 reference

Europe PubMed Central

15 August 2017

1 reference

based on heuristic

inferred from title

author name string

Fei Zhou

1

1 reference

Europe PubMed Central

15 August 2017

Ning Li

2

1 reference

Europe PubMed Central

15 August 2017

Weihua Jiang

3

1 reference

Europe PubMed Central

15 August 2017

Zhaolai Hua

4

1 reference

Europe PubMed Central

15 August 2017

Lin Xia

5

1 reference

Europe PubMed Central

15 August 2017

Qingyi Wei

6

1 reference

Europe PubMed Central

15 August 2017

Liwei Wang

7

1 reference

Europe PubMed Central

15 August 2017

publication date

18 December 2012

1 reference

Europe PubMed Central

15 August 2017

World Journal of Surgical Oncology

1 reference

Europe PubMed Central

15 August 2017

10

1 reference

Europe PubMed Central

15 August 2017

274

1 reference

Europe PubMed Central

15 August 2017

https://scigraph.springernature.com/pub.10.1186/1477-7819-10-274

0 references

Impact of HER-2 overexpression/amplification on the prognosis of gastric cancer patients undergoing resection: a single-center study of 1,036 patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

30 September 2017

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

30 September 2017

Association of ERBB2 gene status with histopathological parameters and disease-specific survival in gastric carcinoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

30 September 2017

HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

30 September 2017

Assessment of a HER2 scoring system for gastric cancer: results from a validation study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

30 September 2017

Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

30 September 2017

HER-2/neu amplification is an independent prognostic factor in gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

30 September 2017

Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

30 September 2017

Her-2/neu and breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

30 September 2017

Basic science of HER-2/neu: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

30 September 2017

HER-2/neu gene amplification status in prostate cancer by fluorescence in situ hybridization

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

30 September 2017

Metastatic gastric cancer - focus on targeted therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

28 June 2018

Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

28 June 2018

Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

20 September 2018

Prognosis of patients with advanced gastric cancer by HER2 status and trastuzumab treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

20 September 2018

HER-2/neu overexpression is an independent prognostic factor for intestinal-type and early-stage gastric cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

20 September 2018

Prognostic implications of altered human epidermal growth factor receptors (HERs) in gastric carcinomas: HER2 and HER3 are predictors of poor outcome.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

20 September 2018

HER-2 amplification is highly homogenous in gastric cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3579675

20 September 2018

[Estimation of cancer incidence and mortality in China in 2004-2005]

1 reference

https://pubmed.ncbi.nlm.nih.gov/23249720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message

1 reference

https://pubmed.ncbi.nlm.nih.gov/23249720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Evaluation of HER2 protein expression in gastric carcinomas: comparative analysis of 1,414 cases of whole-tissue sections and 595 cases of tissue microarrays

1 reference

https://pubmed.ncbi.nlm.nih.gov/23249720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration

1 reference

https://pubmed.ncbi.nlm.nih.gov/23249720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of C-erbB-2 oncoprotein in gastric carcinoma. Immunoreactivity for C-erbB-2 protein is an independent indicator of poor short-term prognosis in patients with gastric carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23249720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Post-transcriptional control of c-erb B-2 overexpression in stomach cancer cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/23249720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

E-cadherin mutations in gastric carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/23249720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Protein overexpression and gene amplification of c-erb B-2 in pulmonary carcinomas: a comparative immunohistochemical and fluorescence in situ hybridization study

1 reference

https://pubmed.ncbi.nlm.nih.gov/23249720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum levels of HER-2 neu (C-erbB-2) correlate with overexpression of p185neu in human ovarian cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23249720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Relationship of C-erbB-2 protein expression and gene amplification to invasion and metastasis in human gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23249720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1477-7819-10-274

1 reference

Europe PubMed Central

15 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

15 August 2017

1 reference

Europe PubMed Central

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36630742&oldid=1642436935"